Skip to main content
SpringerLink
Log in

The Role of Immunosuppression in Lymphoma

  • Conference paper
Immunosurveillance, Immunodeficiencies and Lymphoproliferations

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 159))

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized yet serious complication in solid organ transplant recipients and currently represents the second most common de novo malignancy following solid organ transplantation. PTLD has been noted in all transplant immunosuppressive eras including the pre-cyclosporine, cyclosporine, and post-cyclosporine eras. The time from organ transplantation to PTLD presentation varies widely from less than 1 month to several years. PTLD presents with a broad spectrum of clinical manifestations depending on the transplanted organ, immunosuppressive therapy and patient age. Intense immunosuppressive therapy is a major risk factor for development of PTLD. Whenever a new agent is introduced, there is a learning curve that leads to dosing modifications, which in turn result in optimization of its immunosuppressive efficacy and reduction of toxicities, including PTLD. We review the major historical and recent immunosuppression trials to assess the impact of individual immunosuppressive agents and regimens on PTLD risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Brennan DC, Flavin K, Lowell JA et al. (1999) A randomized, double-blind comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67:1011–1018

    Article  PubMed  CAS  Google Scholar 

  • Calne RY, Rolles K, DJG White et al. (1979) Cyclosporine A: initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet II:1033–1036

    Google Scholar 

  • Canadian Multicenter Transplant Study Group (1983) A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809–815

    Article  Google Scholar 

  • Davis CL, Wood BL, Sabath D E et al. (1998) Interferon alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66:1770–1779

    Article  PubMed  CAS  Google Scholar 

  • European Multicenter Trial Group (1983). Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicenter triaL Lancet II:986–989

    Google Scholar 

  • First MR, VR Peddi (1998) Malignancies complicating organ transplantation. Transplant Proc 30:2768–2770

    Article  PubMed  CAS  Google Scholar 

  • Fukuda M, Aikawa I, Ohmori Y et al. (1987) Chromosome aberrations in kidney transplant recipients. Transplant Proc 19:2245–2246

    PubMed  CAS  Google Scholar 

  • Gaber AO, First MR, Tessi RJ et al. (1998) Results of the double-blind, randomized, multicenter phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66:29–37

    Article  PubMed  CAS  Google Scholar 

  • Groth CG, Backman K, Morales JM et al. (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67:1036–1042

    Article  PubMed  CAS  Google Scholar 

  • Johnson C, Ahsan N, Gonwa T et al. (2000) Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetU versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69:834–841

    Article  PubMed  CAS  Google Scholar 

  • Kahan BD (2000) Efficacy of siroMmus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 356:194–202

    Article  PubMed  CAS  Google Scholar 

  • Kreis H, Cisterne JM, Land W et al. (2000) SiroMmus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69:1252–1260

    Article  PubMed  CAS  Google Scholar 

  • Legendre C, Kreis H (1992) Effect of immunosuppression on the incidence of lymphoma formation. Clin Transplant 6 (Special issue):220–222

    Google Scholar 

  • Mathew T, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1998) A blinded long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 65: 1450–1454

    Article  PubMed  CAS  Google Scholar 

  • Majewski M, Korecka M, Kossev P et aL (2000) The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 97:4285–4290

    Article  PubMed  CAS  Google Scholar 

  • Nalesnik MA (1997) Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 2:33–40

    PubMed  CAS  Google Scholar 

  • Nalesnik MA, Locker J, Jaffe R et al (1982) Experience with post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplant 6 (Special issue):249–252

    Google Scholar 

  • Nashan B, Moore R, Amlot P et al (1997) Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193–1198

    Article  PubMed  CAS  Google Scholar 

  • Nashan B, Light S, Hardie IR, Lin A, Johnson JR (1999) Reduction of acute renal allograft rejection by daclizumab. Transplantation 67:110–115

    Article  PubMed  CAS  Google Scholar 

  • Penn I (1991) The changing pattern of post-transplant malignancies Transplant Proc 23:1101–1103

    PubMed  CAS  Google Scholar 

  • Penn I (1992) Immunosuppression: a contributory factor in lymphoma formation. Clin Transplant 6 (Special issue):214–219

    Google Scholar 

  • Penn I (1996) Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 28:876–878

    PubMed  CAS  Google Scholar 

  • Penn I (2000) Post-transplant malignancy: the role of immunosuppression. Drug Safety 23:101–113

    Article  PubMed  CAS  Google Scholar 

  • Penn I, Hammond W, Brettschnedier L, Starzl T (1969) Malignant lymphomas in transplant patients. Transplant Proc 1:106–112

    PubMed  CAS  Google Scholar 

  • Pirsch ID (1999) Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the US multicenter FK 506 Kidney Transplant Study Group. Transplantation 68:1203–1205

    Article  PubMed  CAS  Google Scholar 

  • Pirsch JD, Miller J, Deierhoi MH, Vincenti R Filo RS, for the FK 506 Kidney Transplant Study Group (1997) A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63:977–983

    Article  PubMed  CAS  Google Scholar 

  • Ratkovec RM, O’Connell JB, Bristow MR et al. (1992) Po st-transplant lymphoproliferative disease in cardiac transplant patients receiving 0KT3 therapy. Clin Transplant 6 (Special issue):260–264

    Google Scholar 

  • Shapiro R, Nalesnick M, McCauley J et al. (1999) Post-transplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 68:1851–1854

    Article  PubMed  CAS  Google Scholar 

  • Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group (1995) Mycophenolate mofetil for the prevention of acute allograft rejection in primary cadaveric renal allograft recipients. Transplantation 60:225–232

    Article  PubMed  CAS  Google Scholar 

  • Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. (1990) Increased incidence of lymphoproEferative disorder after immunosuppression with the monoclonal antibody 0KT3 in cardiac transplant recipients. N Engl J Med 323:1723–1728

    Article  PubMed  CAS  Google Scholar 

  • Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029–1037

    Article  Google Scholar 

  • Wiesner RH (1998) A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the US FK506 Study Group. Transplantation 66:493–499

    Article  PubMed  CAS  Google Scholar 

  • Vincenti F, Kirkman R, Light S, Bumgardner G et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:161–165

    Article  PubMed  CAS  Google Scholar 

  • Younes BS, McDiarmid SV, Martin MG et al. (2000) The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric Ever transplant patients. Transplantation 70:90–94

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, Division of Transplantation, Department of Medicine at University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45267-0558, USA

    Jennifer Trofe, Joseph F. Buell, M. Roy First, Michael J. Hanaway, Tom M. Beebe & E. Steve Woodle

Authors
  1. Jennifer Trofe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph F. Buell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Roy First
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael J. Hanaway
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tom M. Beebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Steve Woodle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Charité-Campus Virchow Medizinische Klinik mit Schwerpunkt Hämatologie/Onkologie, Humboldt Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

    Stephan H. Oertel  & Hanno Riess  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Trofe, J., Buell, J.F., First, M.R., Hanaway, M.J., Beebe, T.M., Woodle, E.S. (2002). The Role of Immunosuppression in Lymphoma. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56352-2_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62676-0

  • Online ISBN: 978-3-642-56352-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation